52234

Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) and/or resection of; MEDIUM bladder tumor(s) (2.0 to 5.0 cm)

CPT code 52234 represents a definitive urological procedure known as a cystourethroscopy combined with the fulguration, destruction, or resection of a medium-sized bladder tumor. A medium tumor is strictly defined by the American Medical Association (AMA) as measuring between 2.0 and 5.0 centimeters in its greatest dimension. This procedure is most frequently performed under general or regional (spinal) anesthesia in an inpatient hospital or ambulatory surgery center setting. The provider utilizes a cystoscope or resectoscope, which is a specialized endoscopic instrument equipped with high-definition optics, a light source, and working channels for specialized surgical tools. The instrument is carefully introduced through the urethral meatus, navigated through the urethra, and advanced into the urinary bladder. Once inside the bladder cavity, the bladder is anatomically distended using a continuous flow of sterile irrigation fluid, allowing for a comprehensive and unimpeded visual examination of the urethral mucosa, the bladder neck, the trigone, and the entire bladder urothelium. The primary objective is the precise identification, clinical evaluation, and targeted eradication of the medium-sized neoplastic lesion(s). Depending on the specific clinical scenario, tumor characteristics, and the urologic surgeon's preference, the destruction or complete removal of the tumor can be achieved through various advanced modalities. These surgical modalities encompass electrofulguration (thermal destruction of the tissue), laser surgery (such as holmium or thulium laser vaporization or enucleation), cryosurgery (freezing the malignant tissue), or, most commonly, transurethral resection of the bladder tumor (TURBT) utilizing a specialized wire loop activated with high-frequency electrical current. If standard loop resection is performed, the excised tissue fragments are subsequently flushed and evacuated from the bladder using an Ellik evacuator or Toomey syringe. These fragments are meticulously collected and submitted to surgical pathology for comprehensive histological analysis, which is critical for determining the grade, depth of invasion, and overall staging of the bladder cancer. Following the complete resection or destruction of the primary tumor mass, the underlying muscular tumor bed and any actively bleeding mucosal vessels are meticulously fulgurated to achieve absolute hemostasis and prevent postoperative hemorrhage. A temporary indwelling Foley catheter is typically placed at the conclusion of the operation to ensure continuous and clear bladder drainage, and to facilitate postoperative continuous bladder irrigation (CBI) if significant hematuria or clot formation is anticipated during the immediate recovery phase. This procedure is highly instrumental not only in the definitive therapeutic management of non-muscle-invasive bladder cancer but also serves an indispensable diagnostic role by providing necessary tissue to determine the precise pathological nature of the urinary mass.

Clinical Indications

  • Primary diagnosis and management of a medium-sized (2.0 to 5.0 cm) bladder mass identified on prior imaging (such as CT urography or pelvic ultrasound).
  • Evaluation and definitive surgical treatment of unremitting gross hematuria or microscopic hematuria linked to a suspected medium bladder neoplasm.
  • Surgical intervention for recurrent non-muscle-invasive bladder cancer presenting with a medium-sized lesion during surveillance cystoscopy.
  • Palliative resection of an actively bleeding medium-sized bladder tumor causing symptomatic anemia or severe lower urinary tract symptoms.
  • Therapeutic transurethral resection of bladder tumor (TURBT) for subsequent histological tissue typing, grading, and staging of urothelial carcinoma.

Procedure Steps

  1. The patient is placed in the dorsal lithotomy position and appropriate general or regional anesthesia is administered.
  2. The external genitalia and urethral meatus are thoroughly prepped with an antiseptic solution and draped in a standard sterile fashion.
  3. A well-lubricated cystoscope or specialized resectoscope is carefully introduced through the urethra and passed into the urinary bladder.
  4. Sterile irrigation fluid (such as sterile water or glycine) is introduced to distend the bladder and establish a clear optical field.
  5. A comprehensive visual inspection of the entire urethra, bladder neck, and bladder mucosa is performed to locate the tumor(s).
  6. The medium-sized tumor, measuring between 2.0 and 5.0 cm, is visually identified, and its size, location, and morphologic characteristics are documented.
  7. Using an electrocautery loop, laser fiber, or fulguration electrode passed through the resectoscope, the tumor is resected, vaporized, or destroyed down to the level of the detrusor muscle.
  8. If resected, the resulting tissue fragments are manually evacuated from the bladder utilizing an Ellik evacuator or Toomey syringe and sent for pathologic evaluation.
  9. The remaining tumor bed and any visibly bleeding vascular structures are systematically fulgurated to achieve rigorous hemostasis.
  10. The bladder is inspected a final time to ensure there is no active bleeding, no perforation, and no remaining tumor fragments.
  11. The resectoscope is carefully withdrawn from the urethra.
  12. A Foley catheter (often a 3-way catheter) is inserted into the bladder to maintain drainage and allow for continuous bladder irrigation (CBI) if deemed necessary.

Coding Guidelines

  • CPT 52234 is specifically for tumors measuring 2.0 to 5.0 cm. For minor tumors less than 2.0 cm, use 52224. For large tumors greater than 5.0 cm, use 52240.
  • When multiple bladder tumors are present and treated during the same operative session, code selection is based solely on the size of the largest tumor. Do not add the sizes of multiple tumors together.
  • A diagnostic cystourethroscopy (52000) is inherently included in 52234 and should not be reported separately.
  • The insertion and removal of a temporary urinary catheter at the time of the procedure is considered an integral component of the surgery and is not separately reportable.
  • Control of bleeding (hemostasis) is bundled into the surgical procedure and cannot be coded in addition to the primary resection.
  • If a biopsy of a completely separate, suspicious area of the bladder is performed (not the tumor being resected), CPT 52204 (Cystourethroscopy, with biopsy) may be reported with an appropriate modifier (e.g., modifier 59), provided the documentation supports a distinct and separate lesion.

Associated ICD-10 Codes